BACKGROUND: This study was initiated to determine whether tumor markers obtained on image-guided breast biopsy specimens provide accurate prognostic information for women with invasive breast cancer. METHODS: Prognostic tumor markers on preoperative image-guided biopsy and final surgical specimens were compared in 44 patients with invasive breast cancer. RESULTS: Progesterone receptor (PR) discordance was 18%. In 87% of PR discordant cases, the image-guided biopsy was positive and the final specimen was negative (P = 0.03). Tumor grade was discordant in 36% of patients Discordance for estrogen receptor (ER) = 2%; MIB-1 = 18%; Her2/neu = 9%; EGFR = 10%; p53 = 9%; and bcl-2 = 0%. The discordance for these markers was random and did not reach statistical significance. CONCLUSION: Image-guided core needle biopsies provide reliable information for the majority of prognostic tumor makers. A positive progesterone receptor is significantly more likely to be determined by core biopsy rather than the final surgical specimen. Tumor grade should be based upon the final surgical specimen whenever possible.
BACKGROUND: This study was initiated to determine whether tumor markers obtained on image-guided breast biopsy specimens provide accurate prognostic information for women with invasive breast cancer. METHODS: Prognostic tumor markers on preoperative image-guided biopsy and final surgical specimens were compared in 44 patients with invasive breast cancer. RESULTS:Progesterone receptor (PR) discordance was 18%. In 87% of PR discordant cases, the image-guided biopsy was positive and the final specimen was negative (P = 0.03). Tumor grade was discordant in 36% of patients Discordance for estrogen receptor (ER) = 2%; MIB-1 = 18%; Her2/neu = 9%; EGFR = 10%; p53 = 9%; and bcl-2 = 0%. The discordance for these markers was random and did not reach statistical significance. CONCLUSION: Image-guided core needle biopsies provide reliable information for the majority of prognostic tumor makers. A positive progesterone receptor is significantly more likely to be determined by core biopsy rather than the final surgical specimen. Tumor grade should be based upon the final surgical specimen whenever possible.
Authors: Zsolt Hodi; Jayeta Chakrabarti; Andrew H S Lee; John E Ronan; Christopher W Elston; Kwok Leung Cheung; John F R Robertson; Ian O Ellis Journal: J Clin Pathol Date: 2006-05-26 Impact factor: 3.411
Authors: T'ng Chang Kwok; Emad A Rakha; Andrew H S Lee; Matthew Grainge; Andrew R Green; Ian O Ellis; Desmond G Powe Journal: Histopathology Date: 2010-08 Impact factor: 5.087
Authors: Gøril Knutsvik; Ingunn M Stefansson; Sura Aziz; Jarle Arnes; Johan Eide; Karin Collett; Lars A Akslen Journal: PLoS One Date: 2014-11-06 Impact factor: 3.240
Authors: Susanne Taucher; Margaretha Rudas; Robert M Mader; Michael Gnant; Peter Dubsky; Sebastian Roka; Thomas Bachleitner; Daniela Kandioler; Günther Steger; Martina Mittlböck; Raimund Jakesz Journal: Wien Klin Wochenschr Date: 2004-01-31 Impact factor: 2.275
Authors: Yalai Bai; Huan Cheng; Jennifer Bordeaux; Veronique Neumeister; Sudha Kumar; David L Rimm; David F Stern Journal: PLoS One Date: 2013-11-21 Impact factor: 3.240